Efficacy and safety of first-line sunitinib in Chinese patients with metastatic renal cell carcinoma

被引：5
|
作者：
Qin, Shu-Kui [1 ]
Jin, Jie [2 ]
Guo, Jun [3 ]
Wang, Jin-Wan [4 ,5 ]
Zhou, Fang-Dian [6 ]
Huang, Yi-Ran [7 ]
Ren, Xiu-Bao [8 ]
Ye, Ding-Wei [9 ]
Pan, Sharon [10 ]
Sajben, Peter [10 ]
Wang, Qiao [11 ]
机构：
[1] Nanjing Bayi Hosp, PLA Canc Ctr, Dept Med Oncol, Nanjing, Jiangsu, Peoples R China
[2] Peking Univ, Hosp 1, Dept Urol, Beijing, Peoples R China
[3] Peking Univ, Canc Hosp & Inst, Dept Renal Canc & Melanoma, Beijing, Peoples R China
[4] Chinese Acad Med Sci, Canc Hosp Inst, Dept Med Oncol, Beijing, Peoples R China
[5] Peking Union Med Coll, Beijing, Peoples R China
[6] Sun Yat Sen Univ, Dept Urol, Canc Ctr, Guangzhou, Guangdong, Peoples R China
[7] Shanghai Renji Hosp, Dept Urol, Shanghai, Peoples R China
[8] Tianjin Med Univ, Canc Inst & Hosp, Dept Biol Treatment, Tianjin, Peoples R China
[9] Fudan Univ, Shanghai Canc Ctr, Dept Urol, Shanghai, Peoples R China
[10] Pfizer Inc, New York, NY 10017 USA
[11] Pfizer Global Res & Dev, Shanghai, Peoples R China
来源：
FUTURE ONCOLOGY | 2018年 / 14卷 / 18期
关键词：
Chinese; metastasis; renal cell carcinoma; sunitinib; targeted therapy; INTERFERON-ALPHA; PHASE-II; JAPANESE PATIENTS; SURVIVAL; HYPERTENSION; BIOMARKERS; SORAFENIB; AXITINIB; THERAPY;
D O I：
10.2217/fon-2017-0733
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Aim: We report the first prospective study of sunitinib for metastatic renal cell carcinoma (mRCC) in China. Methods: Chinese mRCC patients received first-line sunitinib 50 mg daily (4/2 regimen). Overall survival (OS), progression-free survival (PFS), objective response rate and safety were assessed. Potential efficacy biomarkers were explored in post hoc analyses. Results: Median PFS was 61.7 weeks; median OS was 133.4 weeks; objective response rate was 31.1%. Most frequent adverse events (AEs) were: hand-foot syndrome (63.8%), decreased white blood cell count (52.4%), fatigue (51.4%) and decreased platelet count (51.4%). AEs were identified that predicted longer PFS and OS. Conclusion: Sunitinib showed efficacy and manageable AE profile in treatment-naive Chinese mRCC patients. Larger prospective studies are required to confirm identified AEs as predictors of efficacy.
引用
收藏
页码：1835 / 1845
页数：11
相关论文
共 50 条
  • [1] EFFICACY AND SAFETY OF SUNITINIB AS FIRST-LINE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA: SYSTEMATIC REVIEW
    Huerfano, C.
    NinoNino, C. P.
    Davila, F.
    Reyes, J. M.
    Diaz, J. A.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A169 - A169
  • [2] A PHASE IV MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF SUNITINIB AS FIRST-LINE THERAPY IN CHINESE PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
    Qin, S.
    Jin, J.
    Guo, J.
    Wang, J.
    Zhou, F.
    Huang, Y.
    Ren, X.
    Ye, D.
    Wang, Q.
    Pan, S.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 282 - 282
  • [3] Comparison of efficacy, safety,and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma
    Wen Cai
    Wen Kong
    Baijun Dong
    Jin Zhang
    Yonghui Chen
    Wei Xue
    Yiran Huang
    Lixin Zhou
    Jiwei Huang
    [J]. 癌症, 2017, 36 (11) : 574 - 582
  • [4] Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma
    Cai, Wen
    Kong, Wen
    Dong, Baijun
    Zhang, Jin
    Chen, Yonghui
    Xue, Wei
    Huang, Yiran
    Zhou, Lixin
    Huang, Jiwei
    [J]. CHINESE JOURNAL OF CANCER, 2017, 36
  • [5] Efficacy, safety, and prognostic indicators of first-line sunitinib in patients with metastatic renal cell carcinoma: A single center experience
    Abd Ghafar, Nahjatul Kursyiah
    Alip, Adlinda
    Ong, Teng Aik
    Yap, Ning Yi
    Saad, Marniza
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2018, 14 (06) : 1303 - 1311
  • [6] Sunitinib: the First to Arrive at First-Line Metastatic Renal Cell Carcinoma
    Vazquez, Sergio
    Leon, Luis
    Fernandez, Ovidio
    Lazaro, Martin
    Grande, Enrique
    Aparicio, Luis
    [J]. ADVANCES IN THERAPY, 2012, 29 (03) : 202 - 217
  • [7] Sunitinib: the First to Arrive at First-Line Metastatic Renal Cell Carcinoma
    Sergio Vázquez
    Luis León
    Ovidio Fernández
    Martín Lázaro
    Enrique Grande
    Luis Aparicio
    [J]. Advances in Therapy, 2012, 29 : 202 - 217
  • [8] COMPARATIVE EFFICACY OF SUNITINIB VERSUS SORAFENIB AS THE FIRST-LINE TREATMENT FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
    Park, S. J.
    Lee, J.
    Park, I.
    Park, K.
    Ahn, J.
    Lee, D. H.
    Song, C.
    Hong, J. H.
    Kim, C.
    Ahn, H.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 287 - 288
  • [9] Comparative Efficacy of Sunitinib versus Sorafenib as First-Line Treatment for Patients with Metastatic Renal Cell Carcinoma
    Park, Seong Joon
    Lee, Jae-Lyun
    Park, Inkeun
    Park, Kwonoh
    Ahn, Yongcheol
    Ahn, Jin-Hee
    Lee, Dae-Ho
    Ahn, Shin
    Song, Cheryn
    Hong, Jun Hyuk
    Kim, Choung-Soo
    Ahn, Hanjong
    [J]. CHEMOTHERAPY, 2012, 58 (06) : 468 - 474
  • [10] Efficacy and Prognostic Factors of Sunitinib as First-Line Therapy for Patients With Metastatic Renal Cell Carcinoma in an Arab Population
    Badran, Ahmed
    Elshenawy, Mahmoud A.
    Shahin, Amgad
    Aljubran, Ali
    Alzahrani, Ahmed
    Eldali, Abdelmoneim
    Bazarbashi, Shouki
    [J]. JCO GLOBAL ONCOLOGY, 2020, 6 : 19 - 26
12345